By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Arbutus Biopharma (Formerly Known As Tekmira Pharmaceuticals Corporation) 

3805 Old Easton Road
Doylestown, PA 18902

8900 Glenlyon Parkway

Burnaby,  British Columbia,  V5J 5J8  Canada
Phone: 604-419-3200 Fax: 604-419-3201


Arbutus Biopharma Corporation is a publicly-traded (NASDAQ: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

In addition to our HBV Assets, we are developing a pipeline of oncology, anti-viral and metabolic programs that leverage our expertise in RNA interference (RNAi) therapeutics and our Lipid Nanoparticle (LNP) technology.


October 6, 2005


CEO: Mark Murray

CMO (Medical): Mark Kowalski

CFO: Bruce Cousins

CSO (Scientific): Michael Sofia

CTO: Peter Lutwyche


Please click here for Arbutus job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Arbutus Biopharma
Employees: <500 Employees
Symbol: ABUS

Company News
Arbutus Biopharma (ABUS) Is Granted A Pre-Trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology 2/8/2017 7:44:15 AM
Spring Bank Pharmaceuticals, Inc. And Arbutus Biopharma (ABUS) Announce Preclinical Collaboration In Study Of Chronic Hepatitis B 12/19/2016 12:52:43 PM
Arbutus Biopharma (ABUS) Provides Additional Data From The ARB-1467 Phase II Clinical Trial In HBV Patients 12/13/2016 7:13:17 AM
Arbutus Biopharma (ABUS) Presents HBV Drug Combination Studies At American Association for Study of Liver Diseases 11/15/2016 8:05:45 AM
Arbutus Biopharma (ABUS) Provides Corporate Update And Announces Third Quarter 2016 Financial Results 11/4/2016 8:24:53 AM
NeuroVive (NVP) Ends Deal With Arbutus Biopharma (ABUS), Takes Back Hep B Drug 10/21/2016 5:56:26 AM
Arbutus Biopharma (ABUS) To Present HBV Data At The 2016 AASLD Liver Meeting 10/3/2016 7:42:38 AM
Arbutus Biopharma (ABUS) Recognizes Liver Cancer Awareness Month With Grant To Support The Hepatitis B Foundation’s Patient Storytelling Campaign 10/3/2016 7:41:13 AM
Arbutus Biopharma (ABUS) Reports Interim Multi-Dose Results From Phase II Clinical Trial Of ARB-1467 In Patients With Chronic HBV Infection 9/30/2016 7:25:06 AM
Arbutus Biopharma (ABUS)’ Chief Scientific Officer, Dr. Michael J. Sofia, Awarded The 2016 Lasker~Debakey Clinical Medical Research Award 9/13/2016 8:07:53 AM